清肺达原颗粒治疗流感及上呼吸道感染(肺热毒证)的多中心随机双盲安慰剂对照试验
本研究为多中心随机双盲安慰剂对照试验,纳入220例流感及上呼吸道感染(肺热毒证)患者,随机接受清肺达原颗粒15g或安慰剂每日三次共5天。结果显示清肺达原颗粒组完全退热时间缩短至24小时,第3天临床恢复率、咳嗽及鼻塞流涕喷嚏治愈率均高于安慰剂组,且安全性良好。
要点
- 清肺达原颗粒可缩短流感及上呼吸道感染(肺热毒证)患者完全退热时间至24小时。
- 治疗3天后临床恢复率、咳嗽及鼻塞流涕喷嚏治愈率均优于安慰剂。
- 清肺达原颗粒安全性良好,不良事件发生率与安慰剂组无显著差异。
核心结论
- 清肺达原颗粒是治疗流感及上呼吸道感染(肺热毒证)的有效且安全的方法,可缩短完全退热时间、加速临床恢复并缓解咳嗽、鼻塞流涕、喷嚏等症状。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验,纳入湖北省5个城市8家三甲医院的220例合格患者,随机接受清肺达原颗粒15g或安慰剂每日三次共5天。
主要发现
- 清肺达原颗粒组完全退热时间在FAS集为24小时(12.0,48.0),PPS集为24小时(12.0,49.5),均短于安慰剂组(p≤0.001)。
- 治疗3天后,清肺达原颗粒组临床恢复率FAS集为22.3%、PPS集为21.6%,咳嗽治愈率FAS集为38.6%、PPS集为37.9%,鼻塞流涕喷嚏治愈率FAS集为60.0%、PPS集为59.5%,均高于安慰剂组(p<0.05)。
- 安慰剂组使用抗生素超过24小时的患者数(9例)显著高于清肺达原颗粒组(1例)(p<0.05)。
- 两组在中医证候积分、合并症或进展为重症的发生率、对乙酰氨基酚片或化痰药联用及实验室检查方面无显著差异(p>0.05)。
- 两组不良事件发生率和生命体征无显著差异(p>0.05)。
关键数值与推荐
- 完全退热时间:清肺达原颗粒组FAS集24小时(12.0,48.0),PPS集24小时(12.0,49.5),安慰剂组数据原文未报告具体值,组间比较p≤0.001。
- 临床恢复率(治疗3天后):清肺达原颗粒组FAS集22.3%、PPS集21.6%,高于安慰剂组(p<0.05)。
- 咳嗽治愈率(治疗3天后):清肺达原颗粒组FAS集38.6%、PPS集37.9%,高于安慰剂组(p<0.05)。
- 鼻塞流涕喷嚏治愈率(治疗3天后):清肺达原颗粒组FAS集60.0%、PPS集59.5%,高于安慰剂组(p<0.05)。
- 使用抗生素超过24小时的患者数:安慰剂组9例,清肺达原颗粒组1例(p<0.05)。
临床怎么用
- 对于流感及上呼吸道感染表现为肺热毒证的患者,可考虑使用清肺达原颗粒15g每日三次共5天,以缩短退热时间并促进症状缓解。
- 治疗期间应关注患者退热时间及咳嗽、鼻塞流涕喷嚏等症状的改善情况。
- 清肺达原颗粒安全性良好,但仍需监测不良事件和生命体征。
局限性
- 研究仅纳入湖北省5个城市8家医院的患者,结论外推需谨慎。
- 原文未报告安慰剂组完全退热时间的具体数值。
- 研究疗程为5天,长期疗效和安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Patients diagnosed with influenza and upper respiratory tract infections (URTIs) have similar clinical manifestations and biochemical indices and a low detection rate of viral pathogens, mixed infection with diverse respiratory viruses, and targeted antiviral treatment difficulty in the early stage. According to the treatment strategy of "homotherapy for heteropathy" in traditional Chinese medicine (TCM), different diseases with the same clinical symptoms can be treated with the same medicines. Qingfei Dayuan granules (QFDY), a type of Chinese herbal preparation included in the TCM Diagnosis and Treatment Protocol for COVID-19 of Hubei Province issued by the Health Commission of Hubei Province in 2021, are recommended for patients suffering from COVID-19 with symptoms of fever, cough, and fatigue, among others. Additionally, recent studies have shown that QFDY effectively alleviates fever, cough, and other clinical symptoms in patients with influenza and URTIs. Materials and methods: The study was designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial for treatment for influenza and URTIs manifested by pulmonary heat-toxin syndrome (PHTS) with QFDY. A total of 220 eligible patients were enrolled from eight first-class hospitals in five cities of Hubei Province in China and randomly assigned to receive either 15 g of QFDY or a placebo three times a day for 5 days. The primary outcome was the complete fever relief time. Secondary outcomes included efficacy evaluation of TCM syndromes, scores of TCM syndromes, cure rate of each single symptom, incidence of comorbidities and progression to severe conditions, combined medications, and laboratory tests. Safety evaluations mainly involved adverse events (AEs) and changes in vital signs during the study. Results: Compared with the placebo group, the complete fever relief time was shorter in the QFDY group, 24 h (12.0, 48.0) in the full analysis set (FAS) and 24 h (12.0, 49.5) in the per-protocol set (PPS) (p ≤ 0.001). After a 3-day treatment, the clinical recovery rate (22.3% in the FAS and 21.6% in the PPS) and cure rate of cough (38.6% in the FAS and 37.9% in the PPS), a stuffy and running nose, and sneezing (60.0% in the FAS and 59.5% in the PPS) in the QFDY group were higher than those in the placebo group (p < 0.05). The number of patients taking antibiotics for more than 24 h in the placebo group (nine cases) was significantly higher than that in the QFDY group (one case) (p < 0.05). There were no significant differences between the two groups in terms of scores of TCM syndromes, incidence of comorbidities or progression to severe conditions, combined use of acetaminophen tablets or phlegm-resolving medicines, and laboratory tests (p > 0.05). Meanwhile, no significant difference was found in the incidence of AEs and vital signs between the two groups (p > 0.05). Conclusion: The trial showed that QFDY was an effective and safe treatment modality for influenza and URTIs manifested by PHTS because it shortened the complete fever relief time, accelerated clinical recovery, and alleviated symptoms such as cough, a stuffy and running nose, and sneezing during the course of treatment. Clinical trial registration: https://www.chictr.org.cn/showproj.aspx?proj=131702, identifier ChiCTR2100049695.
引用
- Li W, Xie L, Zhu X, et al. Effectiveness and safety of Qingfei Dayuan granules for treating influenza and upper respiratory tract infections manifested by the pulmonary heat-toxin syndrome: A multicenter, randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2023. PMID: 37007028. doi:10.3389/fphar.2023.1133560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。